Overview

This trial is active, not recruiting.

Condition chronic lymphocytic leukemia
Treatments allogeneic stem cell transplantation, alemtuzumab
Phase phase 2
Target CD52
Sponsor Charite University, Berlin, Germany
Collaborator University Hospital Carl Gustav Carus
Start date January 2003
End date April 2009
Trial size 82 participants
Trial identifier NCT00337519, CLL #02, DJCLS-R03/01

Summary

Patients with advanced chronic lymphocytic leukemia (CLL) have a poor long-term prognosis. Allogeneic stem cell transplantation (SCT) in patients with CLL has only rarely been performed in the past because the clinical outcome after myeloablative conditioning was poor, mainly due to the high treatment-related mortality. However long-term disease-free survival after allogeneic SCT has been reported. Recently it has been demonstrated by our group and others that non-relapse mortality can be reduced significantly with the use of reduced-intensity conditioning regimens. Yet, graft versus host disease (GVHD) remains an important problem in this setting.

Alemtuzumab is an effective drug for the treatment of patients with advanced CLL and has been successfully applied for GVHD-prophylaxis in the setting of myeloablative and reduced-intensity conditioning regimens. The goal of the present study is to evaluate the role of alemtuzumab as part of a fludarabine-based reduced intensity conditioning regimen for allogeneic SCT in patients with advanced CLL.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
see detailed description
allogeneic stem cell transplantation
see detailed description
alemtuzumab
alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14

Primary Outcomes

Measure
Progression-free survival
time frame: 400 days

Secondary Outcomes

Measure
safety according to common toxicity criteria (CTC)
time frame: at discharge and until last follow up
rate of primary and secondary graft failure
time frame: until last follow up
rate of acute and chronic GVHD
time frame: day 100 and last follow up
response rate
time frame: 2 years
chimerism
time frame: day 100

Eligibility Criteria

Male or female participants up to 65 years old.

Inclusion Criteria: - written informed consent - sufficient organ function - availability of an HLA-compatible donor (related or unrelated) - age < 65 years - karnofsky index > = 70% - B-CLL requiring treatment after failure of at least one prior cytostatic treatment Exclusion Criteria: - positive HIV-serology - pregnancy - intolerance to study drugs - second neoplasia - serious infections

Additional Information

Official title Chemo-Immunotherapy With Allogeneic Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia (Study #02)
Description Patients with relapsed or refractory CLL who are eligible for the study receive a cytoreductive therapy until SCT. Irrespective to the formal response, patients proceed to allogeneic SCT after fludarabine-based reduced-intensity conditioning. The use of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells > 3 x 10E6 CD34 cells/kg is recommended, but bone marrow > 1 x 10E8 MNC/kg is accepted. GVHD-prophylaxis is based on cyclosporine A adapted to blood levels (150 to 200 ng/mL) over a period of three months. In Phase I of the study, alemtuzumab has been applied as part of the conditioning regimen until day 5. In Phase II, alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14 and after Amendment II in September 2006 scheduled for day 28. Furthermore methotrexate is given on days 1, 3, 6. and 11 at a projected cumulative dose of 45 mg/m2. Subsequent immunosuppressive therapy depends on the occurrence of GvHD, the development of chimerism, and residual disease. Patients with relapsing or residual disease (minimal residual disease excluded) who do not suffer from GvHD should receive donor lymphocytes in increasing dosages. The initial dose is 1 x 105/kg T-cells in unrelated donors and 1 x 106/kg in matched related donors. If no GvHD develops within 6-8 weeks, the next higher dosage is applied.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by Charite University, Berlin, Germany.